The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

Oncology revenue reached $22.4 billion in 2024, with Tagrisso, Lynparza, and Enhertu delivering strong growth. Enhertu's revenue grew 54% in Q4, supported by expanded indications, including HER2 low ...

Second interim dividend declared of $2.10 per share, making a total annual dividend declared for FY 2024 of $3.10 per share, an increase of 7%. Di ...